Mesoblast Ltd is a biotechnology company focused on developing innovative regenerative medicine therapies aimed at addressing significant unmet medical needs. Utilizing its expertise in cellular therapies, the company is advancing treatments for a range of conditions, including chronic inflammatory and degenerative diseases, as well as certain types of cancer. Mesoblast's pioneering work centers on the use of allogeneic cell products, derived from healthy donors, to harness the body’s natural healing processes, with the goal of improving patient outcomes and quality of life. Through rigorous clinical development programs, the company seeks to bring transformative therapies to market that can change the landscape of treatment for various critical health issues.